US Pharma MarketingUS government launches probe into Germany
The US has opened a Section 301 investigation into Germany Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's…
Amid Germany's ongoing review of its healthcare spending, the US government has started a trade investigation into the European country's drug pricing system.
The investigation, under Section 301 of the Trade Act of 1974, heightens ...
Source: Endpoints News